Targets › SLC7A8
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.
Associates with SLC3A2 to form a functional heterodimeric complex that translocates small and large neutral amino acids with broad specificity and a stoichiometry of 1:1. Functions as amino acid antiporter mediating the influx of extracellular essential amino acids mainly in exchange with the efflux of highly concentrated intracellular amino acids. (UniProt, Q9UHI5)
Open in Phaseline: the race on SLC7A8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Brigham and Women's Hospital | 18F-fluciclovine Amino acid transporter targeting radiotracer | SLC7A5, SLC7A8 | Phase 1 | Advanced Prostate Cancer | Sep 2027 |
Advanced Prostate Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.